Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | PHASE1 | RECRUITING | 200 | — | — | Nov 7, 2025 | Apr 1, 2028 | Mar 5, 2026 | 6 | United States |
Best response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
The proportion of participants with best response of CR, PR or Stable Disease (SD) per RECIST V1.1
Time from first occurrence of objective response to the time of Progressive Disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first
Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first
Percentage of participants alive 12 months after first dose of study treatment
| Arm | Type | Description |
|---|---|---|
| Part 1A STRO-004 Monotherapy | EXPERIMENTAL | - |
| Part 1B STRO-004 Monotherapy | EXPERIMENTAL | - |
| Part 1C STRO-004 in Combination with Pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| STRO-004 | DRUG | IV Infusion |
| Pembrolizumab | DRUG | IV Infusion |
Inclusion Criteria: * Histologically or cytologically documented metastatic or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Can...